More than a pen...
Changing the way we diagnose and monitor neuromotor impairments
A unique and patented concept that combines movement related sensor technologies, integrated into a digital pen with an analytical engine and decision support system. Patients perform standardised handwriting and drawing tasks with the unique pen on a tablet computer, which non-invasively records parameters of minute limb and hand motions
What matters most to us
Changing the way we diagnose and monitor neuromotor impairments to improve patients' well being and greater convenience for clinicians.
Our patented technology and unique diagnostic algorithms record validated biomarkers of neuromotor impairments to differentiate between movements and radically improve patient diagnosis and disease management.
We follow strict data management protocols and have a robust, secure data-processing architecture within our cloud-based facility that has been provided by SmartPoints™.
We respect our patients' autonomy and privacy.
Meet the team
Board of Directors
Rutger is founding CEO of Manus Neurodynamica Ltd – the company that created the NeuroMotor Pen (NMP). The NMP is a medical device which objectively and accurately assesses for neuromotor impairments. While working with a small consulting firm, Rutger developed ideas to utilise neuroscience from his earlier PhD research to create novel, easily implementable clinical tools. Manus was founded as a channel to realise those ideas. Rutger coordinated the EU project, DiPAR, which facilitated initial product development and clinical validation. Prior to his PhD, Rutger gained experience in biomedical engineering (J&J Cordis Europe, Philips DAP and Medical systems) and project management for the Dutch healthcare sector (Cap Gemini). He also has post-graduate degrees in Bioengineering and Business administration.
Keith supports Manus Neurodynamica and has been in the life sciences industry for over 30 years, having graduated from Heriot Watt University in Marine Biology and gaining a PhD from the University College of North Wales. Since then, Keith has worked in pharmaceutical development at Covance, Global Head of Life Sciences at PA Consulting Group and Head of Life Sciences Equity Research at Lazard & Co. Keith was Head of Life Sciences Research at Wood Mackenzie for two years before establishing his own consultancy business for life science companies. He joined finnCap in October 2007 with a mandate to build its Life Science franchise and by November 2015, it was the largest in the sector on the Alternative Investment Market. Keith retired from his role in finnCap in April 2016.
Chairman and Non-Executive Director
Richard has played a key role as strategic advisor to Manus Neurodynamica since 2010. He has over 40 years consulting and general management experience, including 17 years with The Boston Consulting Group, where as vice president he led practices in Boston and Milan. As an entrepreneur in the biomedical field, in 1986, Richard founded Bioscience International, Inc., a technology development and transfer company in the life sciences industry, and in 1990, Richard was appointed CEO of Tonometrics Inc, a medical device start-up company that successfully built a worldwide market for its products before being sold to a strategic buyer.
Having graduated in medicine from Kings College in London, Guy practiced in Opthalmology and neurosurgery before moving to a career in business. This has included roles in operations as well as finance. His experience includes drug development at Eli Lilly and working in Healthcare investment banking first as a stock analyst with Barclays de Zoete Wedd and then in mergers and acquisitions with JPMorgan. Investment banking highlights include the demerger of ICI and IPO of Zeneca (now AstraZeneca) and the Wellcome £2.3bn stock offering (the largest in UK corporate history at the time). He subsequently became Chief Executive of Cancer Research Ventures, the technology transfer company for the Cancer Research Campaign. Since then he has been Chairman of Cambridge Cognition Ltd and Chief Executive of Deontics Ltd. which he cofounded and spun out from the University of Oxford. He has been a Trustee of the Royal Society of Medicine and holds an MBA from INSEAD.
Odin previously co-founded Amplyfi Ltd. and was their Chief Machine Intelligence Architect. He developed their initial, novel core AI Technology and brought it to market in the form of DataVoyant which is used over a variety of sectors from Pharma to Finance. Odin holds a MSc (with Distinction) in Knowledge Engineering (Applied AI) and a PhD in Artificial Intelligence from Sunderland University. Odin has extensive experience in secure cloud based solutions, applied Artificial Intelligence and managing multidisciplinary technical projects in general. He has developed the Manus NeuroMotor Pen application and integrated this with the NeuroMotor Pen device alongside the secure cloud based analytics.
Karen supports the management team by providing general office support, running daily operations, as well as coordinating other management activities. She earned a Higher National Diploma in Business Administration from Fife College, and later graduated with a major in European Business Administration from The Robert Gordon University. Karen has worked for big banking firms for over 15 years, while developing administrative, financial, and project management skills. Some of her past roles include Project Senior Analyst at Citibank, Production Leader and Fund Accountant Specialist at JPMorgan Chase, and Client Service Executive at BNY Mellon.
Angus is our Technical Operations and Project Manager. He brings to Manus 35 years postgraduate experience in software development, test management, software quality, operations, people leadership and project management. During that time, he has brought multiple systems and devices to market, most notably key portions of the satellite ground station that serves weather for the whole of Western Europe, and multiple blood glucose meters that have transformed the lives of people with diabetes. Angus spend the first half of his career working in the defence and space industries but made a conscious change in career to focus on improving people’s lives and transitioned into a career in Medical Devices, primarily diabetes care and palliative care for people with cancer, before joining Manus.
Richard Love is Manus' regulatory and QMS manager. Richard's expertise includes international medical device Quality Management System (QMS) implementation to ensure compliance with FDA QSR (cGMP), ISO 13485, MDD (93/42/EEC), MDR (2017/745) and Canadian MDR. Richard has over 25 years of experience with QMS development, auditing, training, coaching and regulatory consulting. Richard is a RAB/QSA (Exemplar Global) certified Lead Auditor (ISO 13485).
Euan has provided leadership in sales, marketing and product management for over 20 years in highly competitive hospital and veterinary markets, where he created marketing strategies and led sales efforts. Euan successfully developed opportunities in new business areas, created new partnerships and established significant revenue growth. As Director of Commercial Growth, Euan is responsible for developing and executing Manus’ sales and marketing strategy.
Senior Data Scientist
Sanja is a medical doctor with a Ph.D. in Regenerative Medicine. She works on clinical collaborations and provides support to clinical and academic users. Before joining the Manus Neurodynamica team, she has worked at Newcastle University for 7 seven years. Her medical expertise enables an understanding of the specific needs of NeuroMotor Pen implementation in both primary care and neurology clinics. She works closely with clinicians and provides valuable feedback that allows constant improvement of the user interface.
Christoforos serves as the Senior Data Scientist of Manus Neurodynamica Ltd. He supports the mission of the company by applying his skills towards further research and development of the NeuroMotor Pen, thus maximizing its potential in clinical practice. He studied informatics at the University of Patras and the University of Edinburgh before embarking on neuroscientific research at Newcastle. He received his PhD from Newcastle University in 2017 and he gained post-doctoral research experience at Newcastle, Sussex and Yale. His research portfolio spans topics from basic neuroscience to computational neurology, with his work being published in highly reputed scientific journals. His expertise in signal processing and statistical modelling provides solutions for intelligent data analysis and efficient extraction of the clinically-useful information from the data collected through our device. He works closely with the Chief Systems Architect of the team to ensure rapid deployment of the analytics algorithms so that they are readily available to our collaborators in the clinics.
Make a difference today
Our disruptive technology has the potential to be used across many applications such as screening and triage, diagnosis, drug treatment optimisation, drug development, rehabilitation and research to improve our understanding of neuromotor impairments. We are keen to continue collaborating with interested researchers, clinicians and practitioners on our research in different areas, as well as businesses for further development and rolling out the existing and new products worldwide.